Animal health group seeks common ground on antibiotics
October 15, 2015
COLORADO SPRINGS, Colo. — "We're all coming to the same conclusion, at the same time," says Dr. Mike Apley, Professor, Production Medicine/ Clinical Pharmacology at Kansas State University and key speaker at the upcoming NIAA-hosted Antibiotics Symposium to be held in Atlanta, November 3-5.
"Animal agriculture, veterinarian medicine, human medicine… we are all seeing that our new antibiotic pipeline is going to be much, much more limited," he says. Apley was interviewed for SwineCast this week on his involvement with the Symposium.
Apley says the Symposium's purpose of working to build a bridge between animal health and human health is important for both mutual fact-checking and to build relationships. "We are all in this together," he says. "We can learn a lot from how each is approaching this. We can't let this break down into Us vs. Them, with lines drawn. We have to make sure we are talking about things together."
The Symposium's theme this year is Antibiotics Stewardship: From Metrics to Management. Apley admits that coming up with a definitive yardstick to measure risk benefits that all parties can agree on will be very difficult. However, the opportunity to have the conversation, face to face, in the same room is what he finds exciting about NIAA's Symposium.
"If we just exchange information through social media or press releases, we're never going to move this anywhere," says Apley. He looks forward to having discussions with people who are dealing with patients, whether those patients are human, food animals or pets, about what they are seeing and hearing. "That's how we are going to find common ground to work together," says Apley.
This is the 5th annual NIAA-hosted Symposium on the subject, bringing together industry experts, academia, public health officials and animal and human health professionals for presentations and discussions, and the second with working sessions on finding a system of measurement to manage this important concern. According to Apley, the US is very data-driven on this issue and the FDA has been instrumental in keeping scientific analysis at the forefront.
Recommended Stories For You